• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Ocular Therapeutix Inc.

    2/24/25 4:33:36 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001653082
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    OCULAR THERAPEUTIX, INC.
    SEC File Number
    001-36554
    Address of Issuer
    15 Crosby Drive
    Bedford
    MASSACHUSETTS
    01730
    Phone
    781-895-3235
    Name of Person for Whose Account the Securities are To Be Sold
    JEFFREY S. HEIER
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    306121043.1515721742702/24/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common02/22/2025Restricted stock vesting under a registered planIssuerCheckbox not checked306102/22/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JEFFREY S. HEIER
    15 Crosby Drive
    Bedford � MA � 01730
    Common11/25/2024294826550.28

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/24/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jeffrey Heier

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OCUL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    4/21/2023$18.00Outperform
    Robert W. Baird
    More analyst ratings

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 5:49:38 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ocular Therapeutix Inc.

      SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/14/24 9:37:26 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

      SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

      11/12/24 4:49:23 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Financials

    Live finance-specific insights

    See more
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

      Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SO

      3/3/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

      BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast Information: Date: Monday, March 3, 2025, at 8:00 AM ET Participant Dial-In (U.S.): 1 (877) 407-9039 Participant Dial-in (International): 1 (201) 689-8470 Conference ID: 13750940 Webcast Access: Please click here The live and archived webcast can also be acce

      2/24/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/27/24 4:43:51 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summer Road Llc bought $4,999,998 worth of shares (1,538,461 units at $3.25) (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      12/18/23 4:52:33 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ocular Therapeutix Inc.

      10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:47:55 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      5/5/25 7:06:05 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ocular Therapeutix Inc.

      DEFA14A - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

      4/29/25 5:01:27 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    See more
    • Ocular Therapeutix® to Host Investor Day on June 13, 2024

      Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

      6/5/24 7:30:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Reports First Quarter 2024 Results

      Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

      5/7/24 4:05:00 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

      Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc

      4/16/24 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights

      AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout SOL-R continues to have strong enrollment through streamlined, accelerated execution Cash balance of $349.7M as of March 31, 2025, with expected runway through topline data for SOL-1 and SOL-R and into 2028 BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a fully-integrated biopharma

      5/5/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences

      BEDFORD, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in the first half of May 2025. Upcoming Investor Conferences Citizens JMP Life Sciences Conference 2025:Fireside Chat Date: Wednesday, May 7, 2025Fireside Chat Time: 9:00 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: New York, NY Bank of America 2025 Global Healthcare Conference:Fireside Chat Date: Tuesday, May 13, 2025Fireside Chat Time: 9:20 AM PTPresenter: Pravin U. Dugel, MD, Executive C

      4/29/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025

      BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The Company will not be hosting a first quarter 2025 conference call and plans to resume quarterly earnings calls for its second quarter 2025 financial results. Information about the Company's quarterly results, conference calls, webcasts and other investor information are posted on the Company's website. About Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

      4/28/25 7:00:00 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dugel Pravin sold $147,533 worth of shares (21,475 units at $6.87), decreasing direct ownership by 0.61% to 3,520,318 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:27:13 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Heier Jeffrey S. sold $21,029 worth of shares (3,061 units at $6.87), decreasing direct ownership by 1% to 265,998 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:25:32 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Kaiser Peter sold $20,672 worth of shares (3,009 units at $6.87), decreasing direct ownership by 1% to 210,078 units (SEC Form 4)

      4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

      2/26/25 6:24:08 PM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Ocular Therapeutix

      William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

      4/8/25 9:29:59 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

      RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

      3/18/25 7:53:57 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Ocular Therapeutix with a new price target

      Needham initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $15.00

      3/11/25 7:42:03 AM ET
      $OCUL
      Biotechnology: Pharmaceutical Preparations
      Health Care